Saturday 17 October 2026
Export BCAB’s income statement to Excel — free account
BioAtla, Inc.
BCAB Healthcare Biotechnology
BioAtla, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 81.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4,233.3%, EPS grew 101.7% and free cash flow grew 97.0%, each against the same quarter a year earlier.
1.36
0.06
+4.62%
Follow BCAB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
1,565.05% | 543.76% | 275.38% | 118.74% | |
| (165.61%) | (179.95%) | (216.05%) | (171.72%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
809.85% | 432.28% | 287.61% | 187.64% | |
Average Days of Receivables |
— | — | — | 41.13 | |
Free Cash Flow per Share |
(48.58) | (40.97) | (24.76) | (14.14) | |
Free Cash Flow |
(57.07) | (48.20) | (37.18) | (23.48) | |
| Other line items | |||||
Cash ROIC |
249.04% | 165.81% | 105.19% | 67.69% | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 143.43% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 85.45% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 22.46% | |
Operating CF/Net income |
0.88 | 0.81 | 0.73 | 0.75 | |
Depreciation/Fixed assets |
1.80 | 3.11 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 10.69 | |
Operating CF per Share |
(48.58) | (40.97) | (24.76) | (14.14) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates